Cagrilintide: what the human research actually shows
An amylin analog that Novo Nordisk is betting can push the incretin-class numbers higher when combined with semaglutide. The Phase 2 data is real and promising; the approval and long-term record are not here yet.
Why I looked into this
Cagrilintide is the quieter half of the CagriSema story. Semaglutide already has approval and the strongest human record of any peptide on this site; CagriSema is Novo Nordisk’s attempt to stack a second mechanism on top of it. The mechanism they picked is amylin activation, an older idea that never quite landed commercially when pramlintide tried it twenty years ago.
What I wanted to understand was whether the Phase 2 combination numbers justify running CagriSema into Phase 3 as a distinct product, and how to think about cagrilintide alone relative to the combination everyone is actually watching.
What Cagrilintide actually is
Cagrilintide is a synthetic long-acting analog of amylin, a hormone released from the pancreatic beta cells alongside insulin after meals. Natural amylin slows gastric emptying, suppresses postprandial glucagon secretion, and signals satiety. The older approved amylin analog pramlintide is short-acting and requires injection with meals. Cagrilintide is engineered with a fatty acid side chain that allows albumin binding and a once-weekly schedule, the same trick that made semaglutide long-acting.
Novo Nordisk is the developer. The compound is investigational as a standalone and is being developed primarily as a fixed-ratio combination with semaglutide under the name CagriSema. CagriSema is the combination Novo is running in the Phase 3 REDEFINE program. Cagrilintide as a standalone is not on any publicly announced path to a separate approval.
What the human research shows
Do published human trials exist?
Yes. Two Phase 2 RCTs in major journals.
The monotherapy trial (Lau et al., Lancet, 2021) tested cagrilintide alone versus placebo in adults with obesity. The combination trial (Enebo et al., Lancet, 2021) tested the CagriSema combination versus semaglutide plus placebo and versus placebo plus placebo, in adults with obesity. The Phase 3 REDEFINE program for CagriSema is ongoing as of April 2026 and has not yet reported final results.
What evidence actually exists?
The key published human data:
- Lau DCW, Erichsen L, Francisco AM, et al. “Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.” Lancet, 2021. Cagrilintide monotherapy across multiple weekly arms, 26 weeks, in adults with overweight or obesity. The trial reported clinically meaningful weight loss at the higher-tested arms, less than what semaglutide monotherapy produces over a similar window. Industry funded (Novo Nordisk).
- Enebo LB, Berthelsen KK, Kankam M, et al. “Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide in participants with overweight or obesity: an investigator-blinded, randomised, multiple-ascending-dose, phase 1b trial.” Lancet, 2021. The 20-week combination trial that first showed CagriSema produces meaningfully greater weight loss than semaglutide alone in the same patients. Industry funded.
- REDEFINE Phase 3 program for CagriSema: multiple ongoing trials, no final readouts in the regulatory record yet.
What the research does not show
The research does NOT show:
- Phase 3 confirmation of CagriSema. The Phase 2 numbers need to hold up at scale.
- An approved standalone role for cagrilintide. Novo is running the combination, not the monotherapy, as the Phase 3 asset.
- Long-term cardiovascular outcomes data. No CV outcomes trial for CagriSema has read out.
- Durability of weight loss after stopping either the combination or the monotherapy.
- That a research-use-only vial labeled cagrilintide or CagriSema is the same compound Novo Nordisk is studying. Gray-market supply is not GMP trial material.
Known safety signals in humans
In the Phase 2 monotherapy trial, the adverse event pattern looked like the broader class: nausea, vomiting, constipation, with higher frequency at higher arms. The combination trial showed an adverse event profile broadly in line with adding a second appetite-suppressing mechanism on top of a GLP-1 agonist, with gastrointestinal symptoms as the main reason for discontinuation in the intervention arms.
What the published record cannot yet tell you is what long-term amylin-receptor activation looks like in a broad real-world population. The older short-acting amylin analog pramlintide has a long safety record, but the long-acting weekly version is new, and the combined mechanism with semaglutide is newer still.
FDA and legal status in the US
Cagrilintide is investigational. There is no approved US pharmacy pathway in 2026, either as a monotherapy or inside CagriSema. The only legitimate way a human uses the compound is inside a Novo Nordisk-run clinical trial under IRB oversight.
The research-use-only gray market has started to sell vials labeled cagrilintide and, in some cases, preparations labeled CagriSema. That material is not the trial-grade supply the Phase 2 and Phase 3 programs are using. It is not manufactured under GMP, not independently verified at the sequence level, and not accompanied by the clinical oversight or informed consent a trial provides. The published evidence base does not automatically transfer to that material.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for Cagrilintide specifically
The specific problem with cagrilintide is that the gray market has begun selling “CagriSema-style” preparations that claim to combine cagrilintide with semaglutide in one vial. That combination is an investigational product under active Phase 3 development. It is not something a research-use-only supplier is in a position to manufacture with the fixed-ratio consistency the Phase 3 protocol requires. The label and the reality are not the same thing.
Cagrilintide sold alone carries the same core source-safety problem as any investigational peptide: there is no legitimate pharmacy reference product to verify identity against, and the only authentic supply is Novo Nordisk trial material.
Cost reality
Research-use-only vials labeled cagrilintide, and combination preparations labeled CagriSema, trade in the gray market at prices similar to other investigational incretins. There is no pharmacy alternative because there is no approved product.
A number attached to an unverified vial is not a quality signal. It is a number attached to material whose contents cannot be confirmed against a pharmaceutical standard.
Questions worth asking any source
- Is this single-molecule cagrilintide or a combination preparation labeled CagriSema? What exactly is in the vial?
- Can you provide a certificate of analysis from an independent lab confirming identity at the sequence level, and, if combination, the fixed ratio claimed?
- Given that cagrilintide is investigational and CagriSema is not approved, what pathway is this material being offered under?
- What is the shelf life and storage specification for this specific lot?
- What is your policy if a customer has an adverse reaction?
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have not used Cagrilintide. Of the next-wave weight-loss compounds, CagriSema is the one most likely to land inside the mechanism space that already has the strongest human record, because the semaglutide half of the combination is already well characterized. That is a different bet than a brand-new triple agonist.
What I am watching for in REDEFINE is not just the weight-loss number but whether the tolerability profile is better or worse than semaglutide alone at equivalent effect sizes. The theoretical appeal of adding amylin activation is that a fraction of the weight-loss effect might come at lower gastrointestinal cost. Whether that actually shows up in Phase 3 is the question the trial is designed to answer.
What I would not do in 2026 is use a research-use-only vial labeled cagrilintide or CagriSema. The approved half of the combination has a pharmacy pathway; the investigational half does not. Combining them yourself, from gray-market supply, is not the experiment the Phase 3 program is running.
For someone curious, read Lau 2021 and Enebo 2021 side by side. The monotherapy paper tells you what cagrilintide does alone; the combination paper tells you what it adds. For someone considering use, the approved incretins already exist and already have the stronger record. For someone weighing CagriSema specifically, the honest answer in 2026 is: wait for REDEFINE.
Questions to ask your doctor
If you are considering Cagrilintide, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- I have read the Lau 2021 cagrilintide monotherapy paper and the Enebo 2021 combination paper. Do you know the literature, and do you see any REDEFINE trial sites still enrolling?
- Given cagrilintide and CagriSema are investigational, what approved incretin options would you consider first for my specific situation, and why?
- If the motivation is to reach effect sizes larger than what semaglutide alone produces, what is your view on the approved options, including tirzepatide, versus waiting for CagriSema?
- If I had used an investigational incretin for a month, what baseline and follow-up labs would you want to check?
- What symptoms would make you want me to stop immediately and contact you, especially with a combination product?
- Is there any legitimate pathway to cagrilintide or CagriSema outside a clinical trial that you are aware of in 2026?
What to do next
Read the two Phase 2 papers
Lau 2021 for cagrilintide monotherapy and Enebo 2021 for the CagriSema combination. Together they tell you what the single mechanism adds to the stack.
Open the primer →Look for a REDEFINE trial
The only legitimate pathway is an ongoing trial. ClinicalTrials.gov lists active REDEFINE sites. Bring the visit-prep packet to your clinician.
Get the packet →Understand what you are buying
Research-use-only cagrilintide or CagriSema is not the trial-grade product the Phase 2 papers studied. Combination claims at the gray-market level are especially unreliable.
Open the checklist →Sources
- Lau DCW, Erichsen L, Francisco AM, et al. “Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.” Lancet. 2021;398(10317):2160-2172. Industry funded (Novo Nordisk). PMID 34798060.
- Enebo LB, Berthelsen KK, Kankam M, et al. “Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide in participants with overweight or obesity: a phase 1b trial.” Lancet. 2021;397(10286):1736-1748. Industry funded (Novo Nordisk). PMID 33894838.
- ClinicalTrials.gov: REDEFINE Phase 3 CagriSema program entries.
- Novo Nordisk investor disclosures on the REDEFINE development timeline.
- FDA-approved pramlintide (Symlin) label, as background on the amylin class.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
Semaglutide
The approved half of the CagriSema combination. Read first, because the combination is semaglutide with a second mechanism stacked on top.
Tirzepatide
The approved dual-agonist that sets the bar CagriSema is trying to clear with a different second-mechanism choice.
Survodutide
A different second-mechanism choice than amylin: glucagon-receptor activation on top of GLP-1. Read alongside CagriSema to see the next-wave landscape.